EMUC 2020

EMUC 2020

EMUC 2020: Hybrid ICG - 99mTc - Nanocolloid, on the Road Towards Becoming the New Standard for Sentinel Node Biopsy in Penile Cancer

(UroToday.com) In a talk presented in the Oral Presentations session of the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. De Vries presented on the role of indocyanine green (ICG) as a tracer in sentinel node biopsy for penile cancer.

EMUC 2020: Organ Preservation in Challenging Cases - Penile Cancer

(UroToday.com) In an oral presentation in the session examining Organ Preservation in Challenging Cases at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Varkarakis and Dr. Parnham discussed the role of organ sparing approaches in penile cancer through a case-based approach.

EMUC 2020: A Subgroup Analysis from the IMvigor130 Study in Patients with Upper Tract vs. Lower Tract Locally Advanced or Metastatic Urothelial Carcinoma Treated with Atezolizumab plus Platinum - Based Chemotherapy

(UroToday.com) In a talk presented in the Oral Presentations session of the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Aristotelis Bamias presented a subgroup analysis from the IMvigor130 trial examining the role of atezolizumab plus platinum-based chemotherapy in patients with locally advanced or metastatic urothelial carcinoma, with stratification according to the primary tumor site.

EMUC 2020: Adjuvant Strategies in Locally Advanced Bladder Cancer

(UroToday.com) In the oral presentations session examining neoadjuvant versus adjuvant strategies in locally advanced bladder cancer at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Maria Ribal led a discussion of adjuvant strategies.

EMUC 2020: Organ Preservation in Bladder Cancer (Trimodal vs Cystectomy)

(UroToday.com) In an oral presentation in the session examining Organ Preservation in Challenging Cases at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Moschini, Dr. Choudhury, and Dr. Roupret discussed a case of organ preservation in bladder cancer.

EMUC 2020: Organ Preservation in Challenging Cases - Testicular Cancer

(UroToday.com) In an oral presentation in the session examining Organ Preservation in Challenging Cases at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Andreas Hiester and Dr. Peter Albers led a discussion regarding organ sparing surgery in testicular cancer.

EMUC 2020: Molecular Sub-Staging of Bladder Cancer: Is It Really Useful?

(UroToday.com) In an oral presentation in the Refining the Treatment of Bladder Cancer session at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Peter Black examined the question of whether molecular subtyping of bladder cancer is useful.

EMUC 2020: Kidney Sparing in Upper Tract Urothelial Cancer

(UroToday.com) At the European Multidisciplinary Congress on Urological Cancers (EMUC) 2020 virtual meeting, Dr. Shahrokh Shariat discussed the role of kidney sparing surgery for upper tract urothelial carcinoma. Dr. Shariat notes that radical nephroureterectomy is not the standard of care for all patients with upper tract urothelial carcinoma, in particular those with low-grade Ta tumors, as it has been estimated that 18-25% of patients may be over-treated (pT0, pTa, pTis) with radical nephroureterectomy. Another reason to avoid over-treatment is the risk of chronic kidney disease, which is common in the population of patients with upper tract urothelial carcinoma. Indeed, prior to radical nephroureterectomy, ~50% of patients have an eGFR < 60 ml/min/1.73m² and after surgery this increases to >75% with have an eGFR < 60 ml/min/1.73m².

EMUC 2020: Partial Nephrectomy in T2 Tumors, Renal Cell Carcinoma

(UroToday.com) The European Multidisciplinary Congress on Urological Cancers (EMUC) 2020 virtual program featured a session on organ preservation in challenging cases, which included a case presentation focused on partial nephrectomy in T2 tumors by Dr. Alessandro Larcher followed by a discussion of this case by Drs. Borje Ljungberg and Hein van Poppel.

EMUC 2020: Regional Treatment of Metastasis: What For?

(UroToday.com) The European Multidisciplinary Congress on Urological Cancers (EMUC) 2020 virtual meeting featured a session on Oligometastatic Disease in Genitourinary Cancers including a presentation by Dr. Steven Joniau discussing the regional treatment of metastases. The rationale for treatment of the primary tumor and metastases in oligometastatic prostate cancer is to “break the chain” whereby aggressive local treatment halts the premetastatic niche and avoids further metastases. Furthermore, efficient treatment of metastases may also stop further metastatic spread and cross-talk with other micrometastases. With regard to oligometastatic disease, the “seek and destroy” method suggests that early and accurate detection of oligometastases provides an opportunity for metastasis-directed treatment with surgery or stereotactic body radiation therapy (SBRT).

EMUC 2020: Oligometastatic Disease in Genitourinary Cancers: Definition and Biology

(UroToday.com) At the Oligometastatic Disease in Genitourinary Cancers session at the 2020 virtual meeting of the European Multidisciplinary Congress on Urological Cancers, Dr. Henk van der Poel discussed important definitions and disease biology. The argument of contiguous versus systemic disease spread dates back to Halsted who suggested that breast cancer is a disease that spreads in an orderly and typically contiguous manner: from the breast to the lymph nodes and then to other distant metastatic sites. However, Fisher suggested that breast cancer is considered a systemic disease at the time of diagnosis. From a urologic perspective, cases of metastasectomy for kidney cancer date back to 1939; a recent systematic review of surgical metastasectomy for patients with renal cell carcinoma suggests that complete resection of disease is associated with 7% long-term survival.^¹

EMUC 2020: Oligometastatic Disease in Genitourinary Cancers: How Reliable is Imaging?

(UroToday.com) The European Multidisciplinary Congress on Urological Cancers (EMUC) 2020 virtual meeting featured a session on Oligometastatic Disease in Genitourinary Cancers including a presentation by Dr. Harriet Thoeny discussing the reliability of imaging. The spectrum of oligometastases is large, including spread from many different primary tumors to different sites (ie. bone, liver, lung), which may be diagnosed with several different imaging modalities, and treated with a variety of options:

EMUC 2020: The Rising Star: PET CT Beyond PSMA - What You Might Not Know About Different & Upcoming Tracers

(UroToday.com) At the Fragments of Imaging session at the European Multidisciplinary Congress on Urological Cancers 2020 virtual meeting, Dr. Frederik Giesel discussed PET CT beyond PSMA imaging, including new tracers that are emerging.

EMUC 2020: Nanoparticles in Prostate Cancer: A Perspective for the Future

(UroToday.com) The European Multidisciplinary Congress on Urological Cancers (EMUC) 2020 virtual meeting featured a discussion of nanoparticles in the Fragments of Imaging session by Dr. Jelle Barentsz. Dr. Barentsz notes that according to the European Association of Urology (EAU) guidelines, pelvic lymph node dissection is the gold-standard for lymph node staging, however, 13% of positive lymph nodes are not detected by pelvic lymph node dissection. According to Dr. Barentsz, the reason for the missed lymph node detection is secondary to surgeons looking for small (<4 mm) lymph nodes deep in the pelvis or higher up in the peri-aortic regions. Because of these nuances and in an effort to improve detection, there is a role for lymph node imaging in these high-risk prostate cancer patients. According to Dr. Barentsz, ⁶⁸Ga-PSMA PET/CT has a poor role in lymph node staging, detecting microscopic disease in only ~9% of high risk patients, secondary to an inability to detect lymph node metastasis when the positive lymph node is <4.0 mm.

EMUC 2020: Ultrasound Is Improving: 29 Mhz, mpUS, C-TRUS, Elastography and Microbubbles

(UroToday.com) At the Fragments of Imaging session at the European Multidisciplinary Congress on Urological Cancers 2020 virtual meeting, Dr. Christophe Mannaerts discussed emerging roles for ultrasound as it relates to prostate cancer detection.

EMUC 2020: Active Surveillance in Intermediate Risk Prostate Cancer

(UroToday.com) The European Multidisciplinary Congress on Urological Cancers (EMUC) 2020 virtual program featured a session on Organ Preservation in Challenging Cases, which included two case presentations focused on active surveillance in intermediate prostate cancer by Dr. Nicola Fossati followed by a discussion of this case by Dr. Mahul Amin.

EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally Advanced Bladder Cancer

(UroToday.com) In an oral presentation in a session examining neoadjuvant versus adjuvant strategies in locally advanced bladder cancer at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Andrea Necchi led a discussion of neoadjuvant strategies in advanced bladder cancer.

EMUC 2020: Management and Survival of Patients with Retroperitoneal Recurrences Following Radical Nephrectomy

(UroToday.com) In a talk presented in the Oral Presentations session of the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Michele Marchioni presented recent work examining the management of patients with retroperitoneal recurrences following radical nephrectomy for renal cell carcinoma. This is a relatively uncommon clinical situation and thus, there is minimal data available to date.

EMUC 2020: Molecular Subtypes of Fully Resected Clear Cell Renal Cell Carcinoma Are Prognostic for Risk of Relapse and May Impact Adjuvant Treatment

(UroToday.com) In a talk presented in the Oral Presentations session of the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Eduard Roussel presented data on the prognostic value of molecularly subtyping in resected renal cell carcinoma.

EMUC 2020: The Need for Confirmatory Biopsies in Patients on Active Surveillance Who Underwent Upfront MRI with Possible Targeted Biopsy

(UroToday.com) In a talk presented in the Oral Presentations session of the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Henk Luiting presented data regarding the somewhat controversial question of the role of a confirmatory biopsy in patients who are undergoing active surveillance diagnosed on the basis of MRI-informed biopsy.